Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hydrix Limited ( (AU:HYD) ) has shared an update.
Hydrix Limited reported consecutive profitable quarters for its services division, driven by improved margins, increased billable utilization, and reduced operating costs. The company achieved a 37% increase in contract sales orders, with significant contributions from international clients and cardiac monitoring products. The recent FDA clearance for Gyder Surgical’s Hip Navigation System underscores Hydrix’s expertise in medical device development and boosts its venture investments. The company anticipates continued sales momentum and revenue growth, supported by a robust sales pipeline and strategic international market engagements.
More about Hydrix Limited
Hydrix Limited operates in the medical technology sector, providing specialized engineering and program management services. The company focuses on cardiac monitoring products and new product development, with a significant presence in international markets, particularly Europe and the USA.
YTD Price Performance: 140.0%
Average Trading Volume: 2,244,726
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$6.55M
For an in-depth examination of HYD stock, go to TipRanks’ Stock Analysis page.